Frédérique Ino

Frédérique Ino

Auto-generated profile, based on publicly available information

Frédérique Ino


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2023 in Cells
Verified
Journal Article
Open access
PDF file
EEElodie Ehret
Elodie Ehret
SSSévan Stroh
Sévan Stroh
MAMuriel Auberson
Muriel Auberson
FIFrédérique Ino
Frédérique Ino
YJYannick Jäger
Yannick Jäger
EHEdith Hummler
Edith Hummler
The serine proteases CAP1/Prss8 and CAP3/St14 are identified as ENaC channel-activating proteases in vitro, highly suggesting that they are required for proteolytic activation of ENaC in vivo. The present study tested whether CAP3/St14 is relevant for renal proteolytic ENaC activation and affects ENaC-mediated Na+ absorption following Na+ deprivation conditions. CAP3/St14 knockout mice exhibit a significant decrease in CAP1/Prss8 protein expression with altered ENaC subunit and decreased pNCC protein abundances but overall maintain sodium balance. RNAscope-based analyses reveal co-expression of CAP3/St14 and CAP1/Prss8 with alpha ENaC in distal tubules of the cortex from wild-type mice. Double CAP1/Prss8; CAP3/St14-deficiency maintained Na+ and K+ balance on a Na+-deprived diet, restored ENaC subunit protein abundances but showed reduced NCC activity under Na+ deprivation. Overall, our data clearly show that CAP3/St14 is not required for direct proteolytic activation of ENaC but for its protein abundance. Our study reveals a complex regulation of ENaC by these serine proteases on the expression level rather than on its proteolytic activation.

20 November 2025 in Hepatology Communications
Verified
Journal Article
Open access
ESEmmanuel Somm
Emmanuel Somm
YJYunju Jo
Yunju Jo
EPElodie Perroud
Elodie Perroud
FIFrédérique Ino
Frédérique Ino
KLKarina Lindner
Karina Lindner
Francois Roland JornayvazFrancois Roland Jornayvaz
Francois Roland Jornayvaz
Background: Metabolic dysfunction–associated steatohepatitis (MASH) is a frequent consequence of Western diet consumption and liver steatosis. IL-18 binding protein (IL-18BP) limits the action of interleukin-18 (IL-18). Our work aims to study the unknown role of IL-18BP in MASH progression. Methods: We analyzed the liver transcriptome from MASH patients. We investigated cell-specific expressions of IL-18, IL-18BP, and IL-18 receptor in human and mouse liver. We studied the liver phenotype of Il18bp −/− mice on a high-fat/high-cholesterol (HFHC) diet. We administered an anti-IL-18 antibody in Il18bp −/− mice and in diet-induced wild-type (WT) MASH mice. We generated and studied double knock-out Il18bp −/− Ifng −/− mice. Results: IL-18BP expression is increased in the liver of patients and mouse models with MASH and positively correlates with fibrosis stages. On the HFHC diet, Il18bp −/− mice exhibit increased hepatic damage, inflammation, and fibrosis compared with WT mice. Treatment with anti-IL-18 antibody corrects liver defects in Il18bp −/− mice and ameliorates inflammation and fibrosis in diet-induced MASH mice, suggesting a translational treatment opportunity. Genetic deficiency in IFN-γ abrogates inflammation but not fibrosis in Il18bp −/− mice. Conclusions: IL-18BP has a role in limiting the progression of MASH, notably by reducing inflammation and fibrosis. Downstream IL-18 over-signaling, IFN-γ, mediates inflammation, but not fibrosis. Increasing IL-18BP levels represents a novel therapeutic perspective for patients affected by MASH.

14 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
EEElodie Ehret
Elodie Ehret
SSSévan Stroh
Sévan Stroh
MAMuriel Auberson
Muriel Auberson
FIFrédérique Ino
Frédérique Ino
YJYannick Jäger
Yannick Jäger
EHEdith Hummler
Edith Hummler
The serine proteases CAP1/Prss8 (prostasin) and CAP3/St14 (matriptase) are identified as ENaC channel-activating proteases in vitro highly suggesting that they are required for proteolytic activation of ENaC in vivo. The present study tested whether CAP3 is relevant for renal proteolytic ENaC activation and affects ENaC-mediated Na+ absorption following Na+-deprivation conditions. CAP3 knockout mice exhibit significant decrease in CAP1 protein expression with altered ENaC subunit and decreased pNCC protein abundances, but overall maintain sodium balance. RNAscope-based analyses reveal co-expression of CAP3 and CAP1 with alpha ENaC in distal tubules of the cortex from wildtype mice. Double CAP1/CAP3-deficiency maintained Na+ and K+ balance on Na+-deprived diet, restored ENaC subunit protein abundances but showed reduced NCC activity under Na+-deprivation. Overall, our data clearly show that CAP3 is not required for direct proteolytic activation of ENaC, but for its protein abundances. Our study reveal a complex regulation of ENaC by these serine proteases on the expression level rather than on its proteolytic activation.

Verified
Journal Article
Open access
PDF file
SPSabrina Pagano
Sabrina Pagano
ESEmmanuel Somm
Emmanuel Somm
CJCatherine Juillard
Catherine Juillard
NLNicolas Liaudet
Nicolas Liaudet
FIFrédérique Ino
Frédérique Ino
Nicolas VuilleumierNicolas Vuilleumier
Nicolas Vuilleumier
Metabolic dysfunction-associated fatty liver disease (MASLD) is a common liver and health issue associated with heightened cardiovascular disease (CVD) risk, with Cytokeratin 18 (CK-18) as a marker of liver injury across the MASLD to cirrhosis spectrum. Autoantibodies against apolipoprotein A-1 (AAA-1s) predict increased CVD risk, promoting atherosclerosis and liver steatosis in apoE−/− mice, though their impact on liver inflammation and fibrosis remains unclear. This study examined AAA-1s’ impact on low-grade inflammation, liver steatosis, and fibrosis using a MASLD mouse model exposed to AAA-1s passive immunization (PI). Ten-week-old male C57BL/6J mice under a high-fat diet underwent PI with AAA-1s or control antibodies for ten days. Compared to controls, AAA-1-immunized mice showed higher plasma CK-18 (5.3 vs. 2.1 pg/mL, p = 0.031), IL-6 (13 vs. 6.9 pg/mL, p = 0.035), IL-10 (27.3 vs. 9.8 pg/mL, p = 0.007), TNF-α (32.1 vs. 24.2 pg/mL, p = 0.032), and liver steatosis (93.4% vs. 73.8%, p = 0.007). Transcriptomic analyses revealed hepatic upregulation of pro-fibrotic mRNAs in AAA-1-recipient mice, though histological changes were absent. In conclusion, short-term AAA-1 PI exacerbated liver steatosis, inflammation, and pro-fibrotic gene expression, suggesting that AAA-1s may play a role in MASLD progression. Further research with prolonged AAA-1 exposure is warranted to clarify their potential role in liver fibrosis and associated complications.